BCDA Stock Summary and Trading Ideas (Biocardia | NASDAQ:BCDA)

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Biocardia trades on the NASDAQ stock market under the symbol BCDA.

As of January 27, 2025, BCDA stock price climbed to $2.27 with 275,503 million shares trading.

BCDA has a beta of 2.60, meaning it tends to be more sensitive to market movements. BCDA has a correlation of 0.12 to the broad based SPY ETF.

BCDA has a market cap of $10.41 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, BCDA traded as high as $43.80 and as low as $1.63.

The top ETF exchange traded funds that BCDA belongs to (by Net Assets): VXF.

BCDA has underperformed the market in the last year with a price return of -67.0% while the SPY ETF gained +24.4%. BCDA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -6.2% and +0.9%, respectively, while the SPY returned +3.9% and +3.1%, respectively.

BCDA support price is $2.02 and resistance is $2.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCDA shares will trade within this expected range on the day.